Silke Frick, Rolf-Dieter Kortmann, Beate Timmermann, Stefan Rutkowski, Nicolas U Gerber, Martin Benesch, Karin Dieckmann, Victor Lewitzki, Albrecht Glück, Semi Ben Harrabi, Christiane Matuschek, Kristin Gurtner, Stefan Dietzsch, Marc Walser, Montserrat Pazos, Rudolf Schwarz, Karolina Jablonska, Dirk Geismar, Martin Mynarek, Tina Schlender, Ralf Kitzing, Julia Remmele, Clemens Seidel, Annett Braesigk
Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] 2021;197(8):674-682
PMID: 33226469
PURPOSE
Several studies have demonstrated the negative impact of radiotherapy protocol deviations on tumor control in medulloblastoma. In the SIOP PNET5 MB trial, a pretreatment radiotherapy quality control (RT-QC) program was introduced. A first analysis for patients enrolled in Germany, Switzerland and Austria with focus on types of deviations in the initial plan proposals and review criteria for modern radiation technologies was performed.
METHODS AND PATIENTS
Sixty-nine craniospinal irradiation (CSI) plans were available for detailed analyses. RT-QC was performed according to protocol definitions on dose uniformity. Because of the lack of definitions for high-precision 3D conformal radiotherapy within the protocol, additional criteria for RT-QC on delineation and coverage of clinical target volume (CTV) and planning target volume (PTV) were defined and evaluated.
RESULTS
Target volume (CTV/PTV) deviations occurred in 49.3% of initial CSI plan proposals (33.3% minor, 15.9% major). Dose uniformity deviations were less frequent (43.5%). Modification of the RT plan was recommended in 43.5% of CSI plans. Unacceptable RT plans were predominantly related to incorrect target delineation rather than dose uniformity. Unacceptable plans were negatively correlated to the number of enrolled patients per institution with a cutoff of 5 patients (p = 0.001).
CONCLUSION
This prospective pretreatment individual case review study revealed a high rate of deviations and emphasizes the strong need of pretreatment RT-QC in clinical trials for medulloblastoma. Furthermore, the experiences point out the necessity of new RT-QC criteria for high-precision CSI techniques.
© 2020. The Author(s).
Full Text Sources:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.